Ziconotide

N-type Calcium Channel Antagonist — NERVOUS SYSTEM

Key facts

Ziconotide is a drug in the N-type Calcium Channel Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2004. Its mechanism of action is classified as N-Calcium Channel Receptor Antagonists. DrugCentral lists 3 molecular targets, including Cacna1b, Cacna1a and CACNA1B. Recorded indications include Chronic pain, Chronic Pain with Opioid Tolerance, Pain in spine and Severe pain.

• Drug class: N-type Calcium Channel Antagonist.
• Mechanism of action: N-Calcium Channel Receptor Antagonists.
• Molecular targets: Cacna1b, Cacna1a and CACNA1B (3 listed in DrugCentral).
• Indications: Chronic pain, Chronic Pain with Opioid Tolerance, Pain in spine and Severe pain.
• ATC code: N02BG08 (Other analgesics and antipyretics).
• Molecular formula: C102H172N36O32S7; molecular weight 2639.14 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Chronic pain
• Chronic Pain with Opioid Tolerance
• Pain in spine
• Severe pain

Contraindications (3)

• Blood coagulation disorder
• Increased Creatine Phosphokinase
• Psychotic disorder

Mechanism & targets

• Mechanism of action (MoA): N-Calcium Channel Receptor Antagonists
• Established pharmacologic class: N-type Calcium Channel Antagonist

Molecular targets (3)

Target	Gene	Action	Activity
Voltage-dependent N-type calcium channel subunit alpha-1B	Cacna1b	blocker	IC50 10.30
Voltage-dependent P/Q-type calcium channel subunit alpha-1A	Cacna1a	blocker	IC50 6.30
Voltage-dependent N-type calcium channel subunit alpha-1B	CACNA1B	blocker	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2004-12-28	FDA	—	JAZZ PHARMS INTL

ATC classification

ATC code	Therapeutic hierarchy
N02BG08	NERVOUS SYSTEM › ANALGESICS › OTHER ANALGESICS AND ANTIPYRETICS › Other analgesics and antipyretics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Device issue	289.1
Hallucination, auditory	193.3
Hallucination	167.8
Confusional state	166.0
Drug withdrawal syndrome	100.7
Mental status changes	93.9
Psychotic disorder	68.3
Hallucination, visual	59.7
Nystagmus	51.6
Withdrawal syndrome	50.8
Urinary retention	46.3
Burning sensation	42.6

Chemical structure

• Molecular formula: C₁₀₂H₁₇₂N₃₆O₃₂S₇
• Molecular weight: 2639.14 g/mol
• CAS number: 107452-89-1
• InChIKey: BPKIMPVREBSLAJ-QTBYCLKRSA-N
• PubChem CID: 16135415

CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)[C@@H](C)O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ziconotide used for?

DrugCentral lists the following indications for Ziconotide: Chronic pain, Chronic Pain with Opioid Tolerance, Pain in spine and Severe pain.

How does Ziconotide work?

Ziconotide is classified as N-Calcium Channel Receptor Antagonists; its molecular targets in DrugCentral include Cacna1b (blocker), Cacna1a (blocker) and CACNA1B (blocker).

When was Ziconotide first approved?

Ziconotide was first approved by the FDA in 2004.

What drug class does Ziconotide belong to?

Ziconotide is in the N-type Calcium Channel Antagonist class.

What is the chemical formula of Ziconotide?

Ziconotide has the molecular formula C102H172N36O32S7 and a molecular weight of 2639.14 g/mol.

Sources

• DrugCentral drug card 2878 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1795072 — compound record and bioactivity
• PubChem CID 16135415 — chemical identifiers
• DrugBank DB06283 — drug record
• FDA UNII 7I64C51O16 — substance identity
• DailyMed: FDA labels for Ziconotide — current prescribing information (label search)
• UniProt Q00975 (CACNA1B) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.